Pharma
-
Permission granted by Sanofi
What Sanofi’s multiple sclerosis troubles could mean for the space
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class.
By Kelly Bilodeau • Jan. 12, 2026 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
Industry execs foresee drug innovation and AI breakthroughs in 2026.
By Meagan Parrish • Jan. 9, 2026 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Theo Wargo via Getty Images
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.
By Michael Gibney • Jan. 8, 2026 -
Alex Wong/ via Getty Images
The wellness industry is HHS’ new belle of the ball
Congressional leaders and health experts are sounding the alarm about potential conflicts of interest among the agency’s new leaders.
By Kelly Bilodeau • Jan. 8, 2026 -
Zmaj88
Year in Preview5 FDA drug approvals to watch in 2026
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.
By Alexandra Pecci • Jan. 7, 2026 -
Getty Images
C-suite priorities give a sneak peek into AI’s pharma future
While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.
By Kelly Bilodeau • Jan. 7, 2026 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Market and policy forces shaping the industry
How pharma leaders believe the regulatory and investment market landscape will change in 2026.
By Meagan Parrish • Jan. 6, 2026 -
Getty Images
3 of China’s most innovative pharma companies
The top Chinese drugmakers succeeding in both innovation and business savvy.
By Kelly Bilodeau • Jan. 5, 2026 -
Alamy
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.
By Alexandra Pecci • Dec. 23, 2025 -
Getty Images
Biopharma CEO optimism is wavering in the US
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
By Kelly Bilodeau • Dec. 22, 2025 -
Permission granted by Biogen
Q&ABiogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.
By Michael Gibney • Dec. 19, 2025 -
Getty Images
The leading GLP-1 contenders in pharma’s race for an obesity pill
Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape.
By Alivia Kaylor • Dec. 18, 2025 -
Getty Images
3 key takeaways from the FDA’s new animal testing guidance
The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.
By Alexandra Pecci • Dec. 17, 2025 -
Retrieved from FDA.
How the FDA could soon upend vaccine trials
Vaccinemakers should be prepared to pivot to meet new requirements by ensuring strong communication.
By Kelly Bilodeau • Dec. 17, 2025 -
Getty Images
5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.
Rapid movement among regulators’ top brass has contributed to an inconsistent strategic direction — but there’s hope in bureaucracy.
By Michael Gibney • Dec. 16, 2025 -
Getty Images
After years of debate, the Biosecure Act could be headed for Trump’s desk
The revised version of the bill softens compliance burdens between U.S. pharma firms and Chinese suppliers, but still has teeth.
By Kelly Bilodeau • Dec. 15, 2025 -
Permission granted by Amylyx Pharmaceuticals
Amylyx pins its next hopes on a niche drug in the obesity space
A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.
By Meagan Parrish • Dec. 12, 2025 -
Courtesy of Johnson & Johnson
Pharma’s top deals in 2025
The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.
By Michael Gibney • Dec. 11, 2025 -
Getty Images
Another genetic testing company? Why a different approach could boost drug predictions and R&D.
Genetic tests could soon play a larger role in clinical trials and predicting adverse events.
By Alexandra Pecci • Dec. 10, 2025 -
Getty Images
Will 2026 be pharma’s M&A breakout year?
Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again.
By Kelly Bilodeau • Dec. 10, 2025 -
Permission granted by Eli Lilly
Q&AHow Lilly uses Big Pharma heft to lift up-and-coming biotechs
With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.
By Michael Gibney • Dec. 9, 2025 -
Getty Images
Standout drug approvals in 2025
Despite ongoing turbulence at the FDA, pharma has delivered several notable breakthroughs to the market.
By Kelly Bilodeau • Dec. 8, 2025 -
IQVIA / Andy Wilson
Sponsored by IQVIA2026: The year AI’s role in pharma shifts from analysis to action
2026 will mark AI’s evolution in pharma, turning intelligence into action across the value chain.
By Prashant Parab • Dec. 8, 2025 -
Getty Images
FDA conflicts of interest extend beyond adcomm experts
Many speakers at public meetings report conflicts while showing support for new drugs, according to recent analysis.
By Meagan Parrish • Dec. 5, 2025 -
Permission granted by BeOne
Q&ABeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
By Michael Gibney • Dec. 4, 2025
